22 July 2025 in Calcified Tissue International
Rheumatoid arthritis (RA) is associated with systemic bone loss and thus an established risk factor for osteoporosis. Janus kinase inhibitors (JAKi) have shown osteo-protective effects. However, clinical data on the effects of baricitinib on bone mineral density (BMD) remain limited. Therefore, we investigated the effects of a 1-year treatment with baricitinib on BMD in RA patients. Patients with active RA beginning treatment with baricitinib were included. BMD was measured at the lumbar spine and femoral neck using Dual-Energy X-Ray Absorptiometry (DXA). Disease activity was assessed using DAS28-CRP and cDAI. The primary endpoint was the change in BMD after 12 months. Secondary endpoints evaluated changes in disease activity, prednisolone dose and alkaline phosphatase (AP) levels and its relation to BMD. A total of 46 RA patients were recruited, of whom 26 completed the study. Overall, BMD remained stable. Non-responders to baricitinib (based on DAS28-CRP) showed a significant decline in spine BMD (− 2.12%, p = 0.039), while responders showed stable BMD. The between-group difference in spine BMD ( p = 0.008) and T-score ( p = 0.012) was significant. Demographic and clinical characteristics did not differ significantly between groups. Disease activity (DAS28-CRP: p = 0.003; cDAI: p = 0.007), prednisolone dose ( p = 0.006), and AP levels ( p = 0.03) all improved significantly. Under baricitinib, BMD loss appeared stabilized in RA patients. Non-responders to baricitinib experienced a significant loss of BMD with a significant difference to responders raising the question if seen effects are achieved by controlling disease activity or if there is an additional explicit JAKi effect on bone metabolism. Trial registration number: DRKS00020780, date: 13.3.2020.
18 December 2025 in Zeitschrift für Rheumatologie
KCKonstantinos Christofyllakis
Konstantinos Christofyllakis
Zusammenfassung: Die nicht-interventionelle Beobachtungsstudie analysierte mit einem retro- und prospektiven Design die Behandlungsrealität von 114 Patienten mit adulter chronisch nicht-bakterieller Osteitis (CNO) an drei deutschen universitären Zentren über den Zeitraum 1985 bis 2025. Primäres Ziel war der Abgleich der Therapieverläufe in Deutschland mit den im Jahr 2024 publizierten internationalen Konsensempfehlungen. Die Empfehlungen favorisieren nichtsteroidale Antirheumatika (NSAR) und Coxibe in der ersten und Tumornekrosefaktor-Inhibitoren (TNFi) oder Bisphosphonate in der zweiten Linie der Therapie. Die Ergebnisse zeigen, dass zwar 61 % zuerst NSAR erhielten, aber nur 20 % in der empfohlenen Ausdosierung der Erstlinientherapie. Hingegen erhielten 46 % der adulten CNO-Patienten in der Erstlinie eine konventionell-synthetische Basistherapie (csDMARDs). Diese wird aufgrund der reduzierten Wirksamkeit aktuell nur in Einzelfällen empfohlen, wenn eine Überlappung der adulten CNO mit axialer Spondylarthritis (axSpA) oder Psoriasisarthritis (PsA) vorliegt. Unsere Daten zeigen, dass eine Überlappung in insgesamt 70 % der adulten CNO-Fälle auftrat. In der zweiten Linie der Therapie kamen wie empfohlen TNFi zum Einsatz, während die alternativ hierzu empfohlenen Bisphosphonate nur bei einem Patienten eingesetzt wurden. Das beobachtete Therapieansprechen betrug, gemessen an der Rate der Therapieabbrüche, innerhalb von 12 Monaten maximal 53 %. Die vorliegenden Daten unterstreichen die Relevanz der aktuellen Empfehlungen zur Vereinheitlichung der Terminologie und zur Optimierung der therapeutischen Versorgung von Patienten mit adulter CNO. Ungelöst bleiben dabei die fehlende ICD-10-Codierung und Zulassung der durch die Konsensempfehlungen vorgeschlagenen Therapie für den deutschen Raum.
26 June 2025 in EULAR Rheumatology Open
Systemic sclerosis (SSc) is associated with an increased risk of osteoporosis. Gastrointestinal manifestations of SSc such as dysphagia and chronic gastritis affect up to 90% of patients and thus may impair the efficacy and safety of oral antiresorptive treatments. However, data on the comparative effectiveness and safety of antiresorptive therapies in SSc are lacking. Patients with SSc treated for osteoporosis at our rheumatology department between 2004 and 2024 were included if they had at least 2 dual-energy X-ray absorptiometry measurements 2 years apart (before and during antiresorptive therapy). Primary endpoint was the change in bone mineral density (BMD). Secondary endpoints assessed changes in BMD for individual drugs, with a specific focus on oral compared with parenterally administered drugs. Adverse events were documented descriptively. A total of 42 patients were included. Overall, antiresorptive therapy significantly improved axial BMD (+3.78%, p = .012), whereas femoral BMD remained unchanged. Subgroup analysis showed a significant axial BMD increase with parenteral therapy (+5.46%, p = .026, n = 21), but not with oral drugs (n = 21). Denosumab yielded the highest axial BMD gain (+7.51%). Overall, no new fractures occurred. One patient developed stage 1 osteonecrosis of the jaw (ONJ) under ibandronate. Three of 19 patients (16%) developed mild gastrointestinal symptoms. No severe gastrointestinal symptoms occurred. Antiresorptive therapies appear to be effective in patients with SSc. Subgroup analysis suggests that parenteral administration, particularly denosumab, may offer superior efficacy. Gastrointestinal adverse effects were mild and consistent with published rates in the general population, whereas ONJ could be more relevant than in the general population.
13 April 2026 in International Journal of Hyperthermia
Up to 95% of patients with systemic sclerosis (SSc) experience Raynaud’s phenomenon (RP), characterized by recurrent digital vasospasm triggered by cold or stress, leading to ischemia, pain, and, i...
21 July 2025 in Zeitschrift für Rheumatologie
5 December 2025 in Calcified Tissue International